LPAR3 and melanoma: These studies are the first to implicate LPA3 as a critical mediator of melanoma growth and survival, and provide evidence that LPA3 mediated receptor signaling may represent an important therapeutic target in melanoma, providing an enhanced benefit of the phosphonothionate analogue.